Skip to content

Effectiveness of gargle and nasal spray with Hydrogen Peroxide as an auxiliary treatment for corona virus

Effectiveness of Hydrogen Peroxide administration in the form of gargle and nasal spray as an auxiliary treatment for suspected and infected patients with SARS-VOC-2

Status
Active, not recruiting
Phases
Phase 2
Study type
Interventional
Source
REBEC
Registry ID
RBR-6sx3sz
Enrollment
Unknown
Registered
2020-07-29
Start date
2020-06-26
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus

Interventions

For the assessment of outcomes, 4 groups of samples will be used (N = 240): Group 1: Hospitalized patients who tested positive for SARS-CoV-2 (n = 40)
Group 2: Family members of hospitalized patients. It is estimated that, for each individual hospitalized, there are 2 more living in the same house (n = 80). Group 3: Patients who sought care, tested

Sponsors

Programa de Pós-Graduação em Odontologia da Universidade de Passo Fundo
Lead Sponsor
Universidade de Passo Fundo
Collaborator

Eligibility

Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: For the index case: test positive for SARS-CoV-2; having received a positive diagnosis less than three days ago; being hospitalized or undergoing home treatment; have the physical capacity to gargle and apply the nasal spray on their own; have moderate or mild symptoms of breathing problems, or have no respiratory symptoms; accept to participate in the study; sign the consent form. For family members of the index case: live in the same household as the individual who tested positive for SARS-CoV-2; have the physical capacity to gargle and apply the nasal spray on their own; have moderate or mild symptoms of breathing problems, or have no respiratory symptoms; accept to participate in the study; sign the consent form.

Exclusion criteria

Exclusion criteria: For index cases: being a smoker; be hospitalized in ICU. For family members in the index case: being hospitalized or having sought hospital care with symptoms suggestive of Covid-19 prior to the index case; have tested positive for Covid-19 before the index case.

Design outcomes

Primary

MeasureTime frame
Need for medical treatment of the patient who was undergoing home treatment or your family member and evolution in clinical symptoms, assessed using questionnaires applied every 2 days.;Results of the rapid test for COVID-19 (IgG / IgM Test, Humasis CO & DFL) of the family member of the index patient, assessed through the Rapid Test.;Need to move the hospitalized patient to the ICU, time between hospitalization and discharge and evolution in clinical symptoms, assessed by monitoring the researchers every 2 days.

Countries

Brazil

Contacts

Public ContactMarielle;Pedro Bazzo Di Domênico;Corazza

Programa de Pós-Graduação em Odontologia da Universidade de Passo Fundo;Programa de Pós-Graduação em Odontologia da Universidade de Passo Fundo

marielledidomenico@gmail.com;pedrocorazza@yahoo.com.br+55 (54) 3316-8395;+55 (54) 3316-8395

Outcome results

None listed

Source: REBEC (via WHO ICTRP)